Author: Ryan Holtz

Ryan Holtz is a Senior Editor at Tech Insider covering Technology & Services sector stocks. His coverage universe includes Chinese Internet stocks in the eCommerce and online video sectors, Chinese online games stocks, as well as education companies. Holtz previously lived in Hong Kong for four years where he served in a dual role as head of Piper Jaffray Asia equity research and senior research analyst covering Chinese stocks. Before joining TI, Ryan was a management consultant at Deloitte & Touche LLC, where he worked in the financial services group.
Analysis, BioTech, business, Earnings

Aegerion Pharmaceuticals (NASDAQ:AEGR) Curbs Losses in Quarter

Aegerion Pharmaceuticals (NASDAQ:AEGR) is lower after it reported a Q4 loss that was smaller than analysts had expected and set a FY14 sales guidance that straddled estimates. Shares are down 11.48% at $58.73 with a 52-week range of $28.33 – $101.00. In the quarter, the biopharmaceutical company had a non-GAAP loss of $0.14 per share, down from a loss of $0.71 the year earlier and … Continue reading Aegerion Pharmaceuticals (NASDAQ:AEGR) Curbs Losses in Quarter

Ryan Holtz
Analyst Actions, Tech IPO

Analyst Pre-Market Upgrades and Downgrades: EPE, BOOM, LNKD, HELI, SQI

LinkedIn (NYSE:LNKD) is higher this morning after RBC upgraded the shares to Outperform from Sector Perform and set a price target of $250 per share, up from $225 per share. JPMorgan analysts have downgraded their coverage of industrial manufacturer Dynamic Materials Corporation (NASDAQ:BOOM) to a Neutral rating from Overweight. The firm also lowered its price target on the stock to $21 from $25 a share. … Continue reading Analyst Pre-Market Upgrades and Downgrades: EPE, BOOM, LNKD, HELI, SQI

Ryan Holtz
Analysis, news

After Market Movers: ANIK, SLRC, PEGA, ZAGG

Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) are up 17.3%, positioning for a new 52-week high of $40.99 if the gains should hold into Wednesday. The stock just came off an evening-session halt after the company said it received FDA marketing approval for MONOVISC, a single injection supplement to synovial fluid of the osteoarthritic joint, used to treat pain and improve joint mobility in patients suffering … Continue reading After Market Movers: ANIK, SLRC, PEGA, ZAGG

Ryan Holtz
BioTech, Popular

Orexigen Therapeutics Sees Shares Slide Pre-Market; Eli Lily Edges Up

Shares of Orexigen Therapeutics (NASDAQ:OREX) slipped in Tuesday’s pre-market session, after the developer of drug treatments for obesity and related disorders said it received a Day 120 List of Questions regarding the marketing authorization application for its NB32 weight-loss drug candidate from the European Medicines Agency’s Committee for Medicinal Products for Human Use. The company said the EMA reviewers’ questions “are consistent with issues raised … Continue reading Orexigen Therapeutics Sees Shares Slide Pre-Market; Eli Lily Edges Up

Ryan Holtz
Analysis, news

Corelogic to Divest Asset Management and Processing Solutions Segment

CoreLogic (NYSE: CLGX) announced that intends to divest its Asset Management and Processing Solutions segment, the area of its business that offers services to banks that allow them to handle their portfolio of foreclosed properties. The segment will now be classified as held for sale, and the company will take a noncash impairment charge of $52 million. The announcement is not a major surprise. Management … Continue reading Corelogic to Divest Asset Management and Processing Solutions Segment

Ryan Holtz
Analysis

Equinix Posts In-Line Results

Equinix (NASDAQ:EQIX) reported solid Q4 results, modestly ahead of the Street and management’s guidance. Based on recurring FCF estimates, the market is already pricing in a favorable REIT conversion ruling, with shares trading at a modest premium to other REITs. Moreover, if the company does not receive a positive ruling, analysts see significant downside in the shares, as the stock would likely trade in line … Continue reading Equinix Posts In-Line Results

Ryan Holtz